Millipore Sigma Vibrant Logo

MABC202 Anti-APC Antibody, clone FE9

Anti-APC Antibody, clone FE9 is an antibody against APC for use in Western Blotting.

Anti-APC Antibody, clone FE9 MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
Research Category: Apoptosis & Cancer Research Sub-Category: Apoptosis - Additional Gene Symbol: APC, DP2.5 UniProt Number: P25054
View Products on Sigmaaldrich.com
MABC202
100 µg  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
—
Request Pricing
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Special Offers

       

      Contact Customer Service

      Overview

      Replacement Information

      Special Offers

      100% Performance Guaranteed

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      HWBMPurifiedMonoclonal Antibody
      Description
      Catalogue NumberMABC202
      DescriptionAnti-APC Antibody, clone FE9
      Alternate Names
      • Adenomatous polyposis coli protein
      • Protein APC
      • Deleted in polyposis 2.5
      Background InformationAdenomatous polyposis coli protein (APC) is a ubiquitous multidomain protein that has a well documented role as a tumor suppressor. The mechanism of APC-mediated tumor suppression is still an area of active investigation; however, several studies suggest that APC is a negative regulator of the Wnt signaling pathway as it downregulates β-catenin via interactions with Axin/GSK3-β complex, thereby preventing transcription of genes such as MYC that contribute to cell proliferation. Defective APC proteins contribute to the initiation and proliferation of various types of cancers, including familial adenomatous polyposis. However, other studies have shown that APC interacts with a range of other proteins such as the EB1 microtubule-binding proteins, to regulate other processes such as cell migration.
      References
      Product Information
      FormatPurified
      Control
      • SW480 cell lysate
      PresentationPurified mouse monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
      Quality LevelMQ100
      Applications
      ApplicationAnti-APC Antibody, clone FE9 is an antibody against APC for use in Western Blotting.
      Key Applications
      • Western Blotting
      Biological Information
      ImmunogenLinear peptide corresponding to the N-terminus of human APC.
      EpitopeN-terminus
      CloneFE9
      ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
      HostMouse
      SpecificityThis antibody recognizes the N-terminus of APC.
      IsotypeIgG1κ
      Species Reactivity
      • Human
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryThis gene encodes a tumor suppressor protein that acts as an antagonist of the Wnt signaling pathway. It is also involved in other processes including cell migration and adhesion, transcriptional activation, and apoptosis. Defects in this gene cause familial adenomatous polyposis (FAP), an autosomal dominant pre-malignant disease that usually progresses to malignancy. Disease-associated mutations tend to be clustered in a small region designated the mutation cluster region (MCR) and result in a truncated protein product.
      Gene Symbol
      • APC
      • DP2.5
      Purification MethodProtein G Purified
      UniProt Number
      UniProt SummaryFUNCTION: Tumor suppressor. Promotes rapid degradation of CTNNB1 and participates in Wnt signaling as a negative regulator. APC activity is correlated with its phosphorylation state. Activates the GEF activity of SPATA13 and ARHGEF4. Plays a role in hepatocyte growth factor (HGF)-induced cell migration. Required for MMP9 up-regulation via the JNK signaling pathway in colorectal tumor cells. Acts as a mediator of ERBB2-dependent stabilization of microtubules at the cell cortex. It is required for the localization of MACF1 to the cell membrane and this localization of MACF1 is critical for its function in microtubule stabilization.

      SUBUNIT STRUCTURE: Forms homooligomers and heterooligomers with APC2. Interacts with DIAPH1 and DIAPH2. Interacts with PDZ domains of DLG1 and DLG3. Associates with catenins. Binds axin. Interacts with ARHGEF4 (via N-terminus). Interacts with MAPRE1 (via C-terminus); probably required for APC targeting to the growing microtubule plus ends. Interacts with MAPRE2 and MAPRE3 (via C-terminus). Found in a complex consisting of ARHGEF4, APC and CTNNB1. Interacts with SCRIB; may mediate APC targeting to adherens junctions of epithelial cells. Interacts with SPATA13 (via N-terminus and SH3 domain). Interacts with ASAP1 (via SH3 domain). Found in a complex composed of MACF1, APC, AXIN1, CTNNB1 and GSK3B.

      SUBCELLULAR LOCATION: Cell junction > adherens junction. Cytoplasm > cytoskeleton. Cell projection > lamellipodium. Cell projection > ruffle membrane. Cytoplasm. Cell membrane. Note: Associated with the microtubule network at the growing distal tip of microtubules. Accumulates in the lamellipodium and ruffle membrane in response to hepatocyte growth factor (HGF) treatment. The MEMO1-RHOA-DIAPH1 signaling pathway controls localization of the phosophorylated form to the cell membrane.

      TISSUE SPECIFICITY: Expressed in a variety of tissues.

      DOMAIN: The microtubule tip localization signal (MtLS) motif; mediates interaction with MAPRE1 and targeting to the growing microtubule plus ends.

      POST-TRANSLATIONAL MODIFICATION:Phosphorylated by GSK3B. Ubiquitinated, leading to its degradation by the proteasome. Ubiquitination is facilitated by Axin. Deubiquitinated by ZRANB1/TRABID.

      INVOLVEMENT IN DISEASE: Defects in APC are a cause of familial adenomatous polyposis (FAP); which includes also Gardner syndrome (GS). FAP and GS contribute to tumor development in patients with uninherited forms of colorectal cancer. FAP is characterized by adenomatous polyps of the colon and rectum, but also of upper gastrointestinal tract (ampullary, duodenal and gastric adenomas). This is a viciously premalignant disease with one or more polyps progressing through dysplasia to malignancy in untreated gene carriers with a median age at diagnosis of 40 years.

      Defects in APC are a cause of hereditary desmoid disease (HDD); also known as familial infiltrative fibromatosis (FIF). HDD is an autosomal dominant trait with 100% penetrance and possible variable expression among affected relatives. HDD patients show multifocal fibromatosis of the paraspinal muscles, breast, occiput, arms, lower ribs, abdominal wall, and mesentery. Desmoid tumors appears also as a complication of familial adenomatous polyposis.

      Defects in APC are a cause of medulloblastoma (MDB). MDB is a malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children. Although the majority of medulloblastomas occur sporadically, some manifest within familial cancer syndromes such as Turcot syndrome and basal cell nevus syndrome (Gorlin syndrome).

      Defects in APC are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots.

      Defects in APC are a cause of gastric cancer (GASC); also called gastric cancer intestinal or stomach cancer. Gastric cancer is a malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.

      Defects in APC are a cause of hepatocellular carcinoma (HCC). This defect includes also the disease entity termed hepatoblastoma.
      Molecular Weight~147 kDa observed. Uniprot describes the full length protein at ~312 kDa. This antibody was shown to detect the truncated form at ~147 kDa.
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceEvaluated by Western Blot in SW480 cell lysate.

      Western Blot Analysis: 0.5 µg/mL of this antibody detected APC in 10 µg of SW480 cell lysate.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at 2-8°C from date of receipt.
      Packaging Information
      Material Size100 µg
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      MABC202 04053252439049

      Documentation

      Anti-APC Antibody, clone FE9 MSDS

      Title

      Safety Data Sheet (SDS) 

      Anti-APC Antibody, clone FE9 Certificates of Analysis

      TitleLot Number
      Anti-APC, clone FE9 - 2394053 2394053
      Anti-APC, clone FE9 - 2397149 2397149
      Anti-APC, clone FE9 - 2540568 2540568
      Anti-APC, clone FE9 - 3190925 3190925
      Anti-APC, clone FE9 - 3317828 3317828
      Anti-APC, clone FE9 - 3690682 3690682
      Anti-APC, clone FE9 - 3826051 3826051
      Anti-APC, clone FE9 - 3977300 3977300
      Anti-APC, clone FE9 - 4003450 4003450
      Anti-APC, clone FE9 - 4054812 4054812
      Show more

      References

      Reference overviewPub Med ID
      Inducible in vivo genome editing with CRISPR-Cas9.
      Dow, LE; Fisher, J; O'Rourke, KP; Muley, A; Kastenhuber, ER; Livshits, G; Tschaharganeh, DF; Socci, ND; Lowe, SW
      Nature biotechnology  33  390-4  2015

      Show Abstract       		25690852 25690852

      Related Products & Applications

      Related Products

      Catalogue Number Description  
      MAB3785 Anti-APC Antibody, NT, clone Ali 12.28 Show Pricing & Availability
      MAB3786 Anti-APC Antibody, CT, clone C-APC 28.9 Show Pricing & Availability
      MAB3786-C Anti-APC Antibody, CT, clone C-APC Antibody 28.9, Ascites Free Show Pricing & Availability
      MABC200 Anti-APC Antibody, clone CC-1 Show Pricing & Availability

      Categories

      Life Science Research > Antibodies and Assays > Primary Antibodies